Landshut/Munich — Bayern Kapital, one of the most experienced and active investors in the high-tech financing landscape, is investing in mbiomics GmbH. The Munich-based company is a pioneer in the field of microbiome biotechnology and is developing the first generation of effective microbiome-based live therapeutics (LBT). In addition to Bayern Kapital, MIG Capital as lead investor as well as High-Tech Gründerfonds and other private investors participated in the first closing of the Series A round with a total volume of EUR 13 million. The closing of the funding round puts mbiomics at the forefront of the emerging field of synthetic microbial consortia, which have the potential to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel disease.
Founded in Munich in 2020, mbiomics GmbH focuses on the development of the first generation of effective bacterial living therapeutics (LBT). The company is using its proprietary, custom profiling platform and computational technologies to generate high-resolution precision data to modulate the microbiota, overcoming current bottlenecks in LBT development. The technology enables a better understanding of the interactions between the gut microbiome and the host, allowing mbiomics to develop more effective microbial consortia that can be delivered to patients as precision therapies. In addition, mbiomics’ core technology improves patient selection and monitoring for clinical trials, creating a competitive advantage.
“The microbiome offers a rich source of new therapeutic opportunities that have not yet been fully explored. Our goal is to harness the power of the microbiome to treat diseases that are difficult to treat with conventional approaches,” explains Dr. Markus Rinecker, co-founder and CMO of mbiomics. “Our outstanding R&D team has delivered a technological proof-of-concept for our analysis platform in record time. With this technology, mbiomics is uniquely positioned to understand the modulation of the microbiome and develop effective therapies,” added Johannes B. Woehrstein, Ph.D., co-founder and CTO.
“We are very pleased to have the support of such a prestigious group of investors who share our vision of harnessing the power of the gut microbiome to develop targeted therapies,” said Laura Figulla, Ph.D., co-founder and CEO of mbiomics. “This funding will allow us to build our platform, accelerate the selection of our first lead product candidates, and intensify research activities with an eye toward clinical validation.”
“The influence of the microbiome on diseases is currently being researched in many ways,” said Monika Steger (photo © Bayern Kapital), managing director of Bayern Kapital. “mbiomics shows great potential in the development of microbiome-based therapeutics for supportive intervention in various diseases and can thus take research a decisive step forward. We look forward to pursuing this path together with the company and an experienced and financially strong investor consortium.”
Dr. Matthias Kromayer, Managing Partner of MIG Capitalcommented: “We are pleased to announce our investment in mbiomics and to support the company on its journey to develop a powerful, innovative therapeutics platform. The company’s approach of combining new technologies with cutting-edge microbiome research is groundbreaking and has the potential to significantly improve treatment outcomes for patients. We look forward to supporting mbiomics’ ongoing research towards clinical development.”
“In the development of “Live Bacterial Products”, microbiome profiling remains one of the major challenges. Mbiomics has developed a novel high-performance profiling platform that addresses key bottlenecks in the development of microbiome-based therapeutic approaches using novel bacterial consortia. We are pleased to invest in an excellent team and an innovative technology together with strong co-investors,” adds Dr. Jan Engels, Investment Manager at High-Tech Gründerfonds.
About Bayern Kapital
Bayern Kapital GmbH, based in Landshut, is the venture/growth capital company of the Free State of Bavaria. It accompanies innovative high-tech companies in the Free State through various growth phases, from seed to later stage, with equity capital in the amount of 0.25 to 25 million euros. Bayern Kapital often fills gaps in the VC sector in proven consortium constellations with private investors (business angels, family offices and corporate ventures).
Bayern Kapital manages specialized investment funds with a volume of around 700 million euros. Since its foundation in 1995 on the initiative of the state government, the wholly owned subsidiary of LfA Förderbank Bayern has so far invested around 400 million euros of its own equity capital in around 300 start-ups and scale-ups in sectors such as life sciences, software & IT, materials & new materials, nanotechnology and environmental technology. As a result, more than 8,000 jobs have been permanently created in Bavaria in sustainable companies. The active portfolio currently comprises over 80 companies.
Examples of numerous groundbreaking success stories that Bayern Kapital has been involved in at an early stage include EOS (today the world’s leading technology provider in industrial 3D printing of metals and plastics), Proglove, Fazua, SimScale, Scompler, egym, Parcellab, Cobrainer, Quantum Systems, Casavi, Riskmethods, Tubulis, Catalym, Immunic, Sirion, tado and many more.
Founded in 2020 and headquartered in Munich, Germany, mbiomics GmbH is a privately held biotech company focused on the development of first generation effective live bacterial therapeutics (LBT). The company is leveraging its custom microbiome diagnostics platform to overcome current bottlenecks in LBT development — generating accurate profiling data, selecting better consortia, and improving patient stratification and monitoring in clinical trials.